ANVISA Clinical Trial Regulations: What Foreign Pharma Must Know in 2025

Key Takeaways

Brazil's pharmaceutical regulator has fundamentally reshaped its clinical trial approval framework, introducing parallel review mechanisms and automatic approval safeguards designed to accelerate investigational drug trials in the country. The National Health Surveillance Agency (ANVISA) implemented Lei 14.874/2024 and RDC 945/2024 effective January 1, 2025, establishing a 90-business-day cap on regulatory review with automatic approval if deadlines are missed. Why it matters: These reforms eliminate sequential approval delays and create predictable timelines for ANVISA drug approval, potentially attracting significantly more foreign pharmaceutical investment to Brazil's clinical trial infrastructure.

ANVISA's Clinical Trial Regulatory Framework: Overview of the 2025 Reforms

Brazil represents a critical market for pharmaceutical development in Latin America, with a population exceeding 215 million and established clinical research infrastructure. However, the country's historical clinical trial approval process has been characterized by extended timelines and sequential review requirements that delayed trial initiation. The new regulatory framework, codified in Lei 14.874/2024 and implemented through RDC 945/2024, represents a structural shift toward efficiency and predictability.

The reform's core innovation is the introduction of a parallel review process whereby ANVISA and local ethics committees simultaneously evaluate clinical trial applications rather than sequentially. This architectural change eliminates a primary source of approval delays. The regulation establishes a hard deadline: ANVISA must complete its review within 90 business days. If the agency fails to issue a decision within this window, automatic approval is granted, removing indefinite regulatory limbo and creating enforceable timelines for trial sponsors.

Under RDC 945/2024, pharmaceutical companies can now submit clinical trial dossiers to both ANVISA and ethics committees concurrently, eliminating the requirement to obtain one approval before proceeding to the other. Additionally, the new regulations streamline import procedures for investigational drugs, reducing customs and logistical barriers that previously extended trial setup timelines. These procedural modifications collectively address bottlenecks in Brazil's clinical trial pathway.

Key Changes in ANVISA's Clinical Trial Approval Process

Parallel Review Architecture: The most significant structural change is the shift from sequential to parallel review. Previously, sponsors often faced delays waiting for ethics committee approval before ANVISA would initiate formal review, or vice versa. The new framework eliminates this dependency chain, allowing both bodies to evaluate applications simultaneously and independently. This parallelization can reduce total approval timelines by weeks or months, depending on the complexity of the application.

90-Business-Day Review Cap with Automatic Approval: ANVISA's review period is now capped at 90 business days (approximately 18 weeks), after which automatic approval is granted if no decision has been issued. This mechanism serves as a critical backstop, ensuring that regulatory delays do not indefinitely stall trial initiation. The automatic approval provision creates enforceable accountability and removes the risk of applications languishing in the review queue—a common complaint from sponsors under the previous system.

Simultaneous Submission Protocol: RDC 945/2024 formally authorizes simultaneous submission of clinical trial applications to ANVISA and ethics committees. This eliminates administrative delays inherent in sequential processing and allows both review bodies to work in parallel. Sponsors can now submit comprehensive dossiers to both entities on the same calendar date, significantly compressing the approval timeline.

Streamlined Investigational Drug Import Procedures: The regulations introduce expedited import pathways for investigational pharmaceuticals, reducing customs clearance times and logistical friction. This procedural efficiency facilitates faster physical availability of trial materials at clinical sites, enabling more rapid trial activation once regulatory approval is obtained.

Regulatory Context and Compliance Framework

The regulatory changes are grounded in Lei 14.874/2024, a legislative act that mandates ANVISA to implement modernized clinical trial oversight mechanisms. RDC 945/2024 is the implementing regulation that translates this legislative directive into operational procedures. The effective date of January 1, 2025, marks the transition point; all clinical trial applications submitted on or after this date are subject to the new parallel review framework and 90-business-day timeline.

Foreign pharmaceutical companies and clinical research organizations (CROs) must ensure compliance with the new submission requirements. Applications must clearly identify all concurrent submissions to ethics committees and must include documentation supporting the investigational drug's safety profile and proposed trial design. ANVISA maintains discretionary authority to request additional information during the 90-business-day review window; such requests do not automatically restart the clock, but clarifications should be provided promptly to avoid approval delays.

The automatic approval provision operates as a legal safeguard, not a guarantee of trial commencement. Sponsors must still satisfy all other regulatory and ethical requirements; automatic approval simply means that ANVISA's formal authorization is granted if no adverse determination is issued within the prescribed timeframe. Ethics committee approval remains independently required and is not subject to automatic approval under these regulations.

Implications for Foreign Pharmaceutical Companies and Trial Sponsors

The regulatory reforms substantially reduce barriers to clinical trial initiation in Brazil for foreign pharmaceutical sponsors. Compared with the previous sequential review model, the parallel process eliminates weeks or months of administrative delay. The 90-business-day cap provides unprecedented timeline predictability, enabling sponsors to forecast trial startup dates with confidence and integrate Brazilian sites into global development programs more efficiently.

For foreign companies conducting General Clinical Trials in Brazil, the streamlined approval process reduces the regulatory risk premium historically associated with the market. Companies can now justify including Brazilian sites in pivotal trials without assuming the regulatory timeline uncertainty that previously made such decisions difficult. This regulatory clarity is expected to attract increased foreign investment in Brazil's clinical research infrastructure.

However, sponsors must recognize that parallel review requires simultaneous engagement with both ANVISA and local ethics committees. This dual-track approach demands coordinated submission strategy and clear communication with both bodies. Sponsors should engage regulatory consultants familiar with ANVISA's expectations and local ethics committee requirements to optimize dossier quality and reduce the risk of information requests that could delay review.

The streamlined import procedures reduce logistical friction but do not eliminate it. Sponsors should initiate import arrangements early and coordinate with local partners to ensure investigational drugs are physically available at clinical sites immediately upon regulatory approval. Delays in drug availability after approval can undermine the efficiency gains from accelerated regulatory review.

Strategic Considerations for Market Entry and Drug Approval Pathway Integration

Accelerated clinical trial approvals in Brazil have downstream implications for drug approval timelines and market entry strategy. Trials conducted in Brazil under the new regulatory framework can generate efficacy and safety data that support ANVISA drug approval applications, potentially shortening the time between trial completion and marketing authorization.

Foreign companies should consider Brazil as a strategic location for late-phase trials in therapeutic areas where the country has established patient populations and clinical research infrastructure. Oncology, infectious disease, and cardiovascular disease trials are particularly well-suited to Brazilian sites. Including Brazil in global trial networks can accelerate overall development timelines while generating region-specific safety and efficacy data that strengthens ANVISA drug approval submissions.

Early engagement with ANVISA during trial planning—before formal application submission—is advisable. Regulatory meetings with ANVISA can clarify expectations, identify potential compliance issues, and optimize trial design for Brazilian regulatory acceptance. This pre-submission dialogue reduces the likelihood of information requests during the 90-business-day review window and increases the probability of approval within the prescribed timeframe.

What to watch next: Sponsors should monitor ANVISA's implementation of the new regulations during the first quarter of 2025 to identify any procedural clarifications or guidance documents that may be issued. Early feedback from companies submitting under the new framework will inform best practices and optimal submission strategies.

Future Outlook: Brazil's Evolving Role in Latin American Clinical Research

ANVISA's regulatory reforms are expected to increase clinical trial volume in Brazil over the next 12–24 months. The combination of reduced approval timelines, streamlined procedures, and enhanced predictability creates a more attractive environment for foreign pharmaceutical sponsors. This regulatory acceleration may position Brazil as the preferred Latin American hub for clinical research, drawing trials that might otherwise be conducted in Mexico, Argentina, or other regional markets.

The regulatory changes may also catalyze broader harmonization efforts across Latin America. As other regional regulators observe Brazil's modernized framework, pressure may mount for similar reforms in neighboring countries. ANVISA's experience with parallel review and automatic approval mechanisms may serve as a model for regulatory modernization across LATAM, potentially creating a more integrated regional clinical trial infrastructure.

Ongoing regulatory monitoring is essential for sponsors. ANVISA may issue additional guidance documents, clarifications, or procedural updates as the new framework is operationalized. Industry associations and regulatory consultants should track regulatory announcements to ensure compliance with evolving expectations.

The long-term impact of these reforms extends beyond clinical trial timelines to Brazil's competitive positioning in global pharmaceutical development. By reducing regulatory barriers and accelerating trial approvals, ANVISA enhances Brazil's attractiveness for foreign pharmaceutical investment, clinical research employment, and technology transfer. These factors collectively strengthen Brazil's role in the global pharmaceutical development ecosystem.

Frequently Asked Questions

References

1. National Health Surveillance Agency (ANVISA). Lei 14.874/2024 and RDC 945/2024: Clinical Trial Approval Framework. Effective January 1, 2025. Parallel review process with 90-business-day cap and automatic approval provision for clinical trial applications.